First oral GLP-1 cuts cardiovascular risk by 14% – and it’s now FDA-approved
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk’s once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke. Continue Reading Category: Diabetes, Illnesses and conditions, Body and Mind Tags: Novo Nordisk, Heart Disease, Cardiovascular […]
Lilly’s oral GLP-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Reconfirming Its Potential as a Foundational Treatment in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron…
Doctors Just Found Something Fascinating About What Happens When You Drink on Ozempic
GLP-1 drugs like semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, were originally intended to treat diabetes — and didn’t become blockbuster prescriptions until doctors realized that they were also potent weight loss aids that seem to re-wire patients’ relationship to food and satiety. Since then, it’s slowly been emerging that they have […]
Fight Aging! Newsletter, October 20th 2025
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/. To unsubscribe, send email or reply to […]
Greggs shares: it can’t go on like this, can it?
I donât know what inspired the Mick McCarthy reference in the title, but sadly, Iâm not very optimistic about Greggs (LSE:GRG) shares. And while I feel for the company and everyone who may benefit from an elevated share price, itâs great to see the stock return to more manageable valuation multiples. On a forward basis, […]
We Need to Quickly Find Out If GLP-1s Help With Addiction
Early research on using GLP-1 drugs as an addiction treatment is promising, as are the anecdotes we hear. But formal clinical data is limited, and in an opinion piece for the New York Times , Maia Szalavitz argues that needs to change—fast. “Unlike new drug compounds that take years to…
Surgery beats Ozempic for long-term health, Cleveland Clinic finds
Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
Novo Nordisk GLP-1 pill now U.S. approved for heart disease risk
Novo Nordisk GLP-1 pill now U.S. approved for heart disease risk
This Stellar Vanguard ETF Is Beating the VTI and VOO This Year
Key Points The VOO and VTI are exceptional Vanguard ETFs, but the VGK is a worthy complement, especially for investors who want more of a value tilt. Diversifying internationally may be viewed as overrated for some. But amid climbing multiples in U.S. stocks, I think the case for expanding internationally is strengthening. It’s cheap to […]